Skip Navigation
Skip to contents

JPTM : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Previous issues

Page Path
HOME > Articles and issues > Previous issues
12 Previous issues
Filter
Filter
Article category
Keywords
Authors
Funded articles
Volume 50(3); May 2016
Prev issue Next issue
Review
Pathologic Evaluation of Breast Cancer after Neoadjuvant Therapy
Cheol Keun Park, Woo-Hee Jung, Ja Seung Koo
J Pathol Transl Med. 2016;50(3):173-180.   Published online April 11, 2016
DOI: https://doi.org/10.4132/jptm.2016.02.02
  • 11,735 View
  • 365 Download
  • 26 Citations
AbstractAbstract PDF
Breast cancer, one of the most common cancers in women, has various treatment modalities. Neoadjuvant therapy (NAT) has been used in many clinical trials because it is easy to evaluate the treatment response to therapeutic agents in a short time period; consequently, NAT is currently a standard treatment modality for large-sized and locally advanced breast cancers, and its use in early-stage breast cancer is becoming more common. Thus, chances to encounter breast tissue from patients treated with NAT is increasing. However, systems for handling and evaluating such specimens have not been established. Several evaluation systems emphasize a multidisciplinary approach to increase the accuracy of breast cancer assessment. Thus, detailed and systematic evaluation of clinical, radiologic, and pathologic findings is important. In this review, we compare the major problems of each evaluation system and discuss important points for handling and evaluating NAT-treated breast specimens.

Citations

Citations to this article as recorded by  
  • Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer
    Maryam Nemati Shafaee, Shalini Makawita, Bora Lim, Matthew J Ellis, Michelle S Ludwig
    Clinical Breast Cancer.2022; 22(4): e536.     CrossRef
  • Pathology after neoadjuvant treatment – How to assess residual disease
    Giuseppe Viale, Nicola Fusco
    The Breast.2022; 62: S25.     CrossRef
  • Efficacy Evaluation of Neoadjuvant Chemotherapy in Breast Cancer by MRI
    Yongguang Liu, Mingxiang Wu, Wenyong Tan, Jingshan Gong, Jie Ma, Mohammad Farukh Hashmi
    Contrast Media & Molecular Imaging.2022; 2022: 1.     CrossRef
  • Predictive Role of Soluble IL-6R, TNF-R1/2, and Cell Adhesion Molecules Serum Levels in the Preoperative and Adjuvant Therapy in Women with Nonmetastatic Breast Cancer: A Preliminary Study
    Weronika Bulska-Będkowska, Paulina Czajka-Francuz, Sylwia Cisoń-Jurek, Aleksander J. Owczarek, Tomasz Francuz, Jerzy Chudek
    Journal of Interferon & Cytokine Research.2022; 42(11): 557.     CrossRef
  • The prognostic role of lymph node ratio in breast cancer patients received neoadjuvant chemotherapy: A dose-response meta-analysis
    Jinzhao Liu, Yifei Li, Weifang Zhang, Chenhui Yang, Chao Yang, Liang Chen, Mingjian Ding, Liang Zhang, Xiaojun Liu, Guozhong Cui, Yunjiang Liu
    Frontiers in Surgery.2022;[Epub]     CrossRef
  • The Role of miR-375-3p, miR-210-3p and Let-7e-5p in the Pathological Response of Breast Cancer Patients to Neoadjuvant Therapy
    Lorena Alexandra Lisencu, Andrei Roman, Simona Visan, Eduard-Alexandru Bonci, Andrei Pașca, Emilia Grigorescu, Elena Mustea, Andrei Cismaru, Alexandru Irimie, Cosmin Lisencu, Loredana Balacescu, Ovidiu Balacescu, Oana Tudoran
    Medicina.2022; 58(10): 1494.     CrossRef
  • Post-Neoadjuvant Treatment Strategies for Patients with Early Breast Cancer
    Elisa Agostinetto, Flavia Jacobs, Véronique Debien, Alex De Caluwé, Catalin-Florin Pop, Xavier Catteau, Philippe Aftimos, Evandro de Azambuja, Laurence Buisseret
    Cancers.2022; 14(21): 5467.     CrossRef
  • Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment
    Joshua J. Li, Julia Y. Tsang, Gary M. Tse
    Cancers.2021; 13(16): 4233.     CrossRef
  • SPIE-AAPM-NCI BreastPathQ challenge: an image analysis challenge for quantitative tumor cellularity assessment in breast cancer histology images following neoadjuvant treatment
    Nicholas Petrick, Shazia Akbar, Kenny H. Cha, Sharon Nofech-Mozes, Berkman Sahiner, Marios A. Gavrielides, Jayashree Kalpathy-Cramer, Karen Drukker, Anne L. Martel, for the BreastPathQ Challenge Group
    Journal of Medical Imaging.2021;[Epub]     CrossRef
  • Diagnostic performance of digital breast tomosynthesis for predicting response to neoadjuvant systemic therapy in breast cancer patients: A comparison with magnetic resonance imaging, ultrasound, and full-field digital mammography
    Ryusuke Murakami, Hitomi Tani, Shinichiro Kumita, Nachiko Uchiyama
    Acta Radiologica Open.2021; 10(12): 205846012110637.     CrossRef
  • Los márgenes
    Laia Bernet, María Angeles Montero Fernández
    Revista de Senología y Patología Mamaria.2021; 34: S25.     CrossRef
  • Neoadjuvant chemotherapy in non‐metastatic breast cancer: a study on practice trends in a regional cancer treatment service
    Edmond Ang, Navin Wewala, Rebecca Carroll, Garry Forgeson, Malcolm Anderson, Jennifer Fernando, Jody Jordan, Richard Isaacs
    Internal Medicine Journal.2020; 50(3): 315.     CrossRef
  • Examination of Tumor Regression Grading Systems in Breast Cancer Patients Who Received Neoadjuvant Therapy
    Anita Sejben, Renáta Kószó, Zsuzsanna Kahán, Gábor Cserni, Tamás Zombori
    Pathology & Oncology Research.2020; 26(4): 2747.     CrossRef
  • Integrating evolutionary dynamics into cancer therapy
    Robert A. Gatenby, Joel S. Brown
    Nature Reviews Clinical Oncology.2020; 17(11): 675.     CrossRef
  • Assessing the accuracy of conventional gadolinium‐enhanced breast MRI in measuring the nodal response to neoadjuvant chemotherapy (NAC) in breast cancer
    Lisa Christine Murphy, Edel Marie Quinn, Zeeshan Razzaq, Claire Brady, Vicki Livingstone, Lorna Duddy, Josephine Barry, Henry Paul Redmond, Mark Anthony Corrigan
    The Breast Journal.2020; 26(11): 2151.     CrossRef
  • Early prediction of neoadjuvant chemotherapy response for advanced breast cancer using PET/MRI image deep learning
    Joon Ho Choi, Hyun-Ah Kim, Wook Kim, Ilhan Lim, Inki Lee, Byung Hyun Byun, Woo Chul Noh, Min-Ki Seong, Seung-Sook Lee, Byung Il Kim, Chang Woon Choi, Sang Moo Lim, Sang-Keun Woo
    Scientific Reports.2020;[Epub]     CrossRef
  • Patterns of Regression in Breast Cancer after Primary Systemic Treatment
    Tamás Zombori, Gábor Cserni
    Pathology & Oncology Research.2019; 25(3): 1153.     CrossRef
  • The Role of Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Predicting Neoadjuvant Chemotherapy Response in Breast Cancer
    Hee Yeon Kim, Tae Hyun Kim, Hye Kyoung Yoon, Anbok Lee
    Journal of Breast Cancer.2019; 22(3): 425.     CrossRef
  • Higher underestimation of tumour size post-neoadjuvant chemotherapy with breast magnetic resonance imaging (MRI)—A concordance comparison cohort analysis
    Wen-Pei Wu, Hwa-Koon Wu, Chih-Jung Chen, Chih-Wie Lee, Shou-Tung Chen, Dar-Ren Chen, Chen-Te Chou, Chi Wei Mok, Hung-Wen Lai, Pascal A. T. Baltzer
    PLOS ONE.2019; 14(10): e0222917.     CrossRef
  • Multimodal image-guided surgery of HER2-positive breast cancer using [111In]In-DTPA-trastuzumab-IRDye800CW in an orthotopic breast tumor model
    Marion M. Deken, Desirée L. Bos, Willemieke S. F. J. Tummers, Taryn L. March, Cornelis J. H. van de Velde, Mark Rijpkema, Alexander L. Vahrmeijer
    EJNMMI Research.2019;[Epub]     CrossRef
  • Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer
    Ida Skarping, Daniel Förnvik, Hanna Sartor, Uffe Heide-Jørgensen, Sophia Zackrisson, Signe Borgquist
    BMC Cancer.2019;[Epub]     CrossRef
  • ALDH1 and tumor infiltrating lymphocytes as predictors for neoadjuvant chemotherapy response in breast cancer
    Anbok Lee, Kyu Yeoun Won, Sung-Jig Lim, Sun Young Cho, Sang-Ah Han, SaeGwang Park, Jeong-Yoon Song
    Pathology - Research and Practice.2018; 214(5): 619.     CrossRef
  • Early Prediction of Response to Neoadjuvant Chemotherapy Using Dynamic Contrast-Enhanced MRI and Ultrasound in Breast Cancer
    Yunju Kim, Sung Hun Kim, Byung Joo Song, Bong Joo Kang, Kwang-il Yim, Ahwon Lee, Yoonho Nam
    Korean Journal of Radiology.2018; 19(4): 682.     CrossRef
  • Outcomes of neoadjuvant and adjuvant chemotherapy in stage 2 and 3 non-small cell lung cancer: an analysis of the National Cancer Database
    Matthew MacLean, Xin Luo, Shidan Wang, Kemp Kernstine, David E. Gerber, Yang Xie
    Oncotarget.2018; 9(36): 24470.     CrossRef
  • Automatic cellularity assessment from post-treated breast surgical specimens
    Mohammad Peikari, Sherine Salama, Sharon Nofech-Mozes, Anne L. Martel
    Cytometry Part A.2017; 91(11): 1078.     CrossRef
  • The importance of tissue confirmation of metastatic disease in patients with breast cancer: lesson from a brain metastasis case
    Jingxian Ding, Pinghua Hu, Jun Chen, Xiaobo Wu, Yali Cao
    Oncoscience.2016; 3(9-10): 268.     CrossRef
Original Articles
Nuclear Expression of Hepatitis B Virus X Protein Is Associated with Recurrence of Early-Stage Hepatocellular Carcinomas: Role of Viral Protein in Tumor Recurrence
Jing Jin, Hae Yoen Jung, KyuHo Lee, Nam-Joon Yi, Kyung-Suk Suh, Ja-June Jang, Kyoung-Bun Lee
J Pathol Transl Med. 2016;50(3):181-189.   Published online April 17, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.18
  • 16,731 View
  • 94 Download
  • 4 Citations
AbstractAbstract PDF
Background
Hepatitis B virus (HBV) plays well-known roles in tumorigenesis of hepatocellular carcinoma (HCC) in infected patients. However, HBV-associated protein status in tumor tissues and the relevance to tumor behavior has not been reported. Our study aimed to examine the expression of HBV-associated proteins in HCC and adjacent nontumorous tissue and their clinicopathologic implication in HCC patients.
Methods
HBV surface antigen (HBsAg), HBV core antigen (HBcAg), and HBV X protein (HBx) were assessed in 328 HBV-associated HCCs and in 155 matched nontumorous tissues by immunohistochemistry staining.
Results
The positive rates of HBsAg and cytoplasmic HBx staining in tumor tissue were lower than those in nontumorous tissue (7.3% vs. 57.4%, p < .001; 43.4% vs. 81.3%, p < .001). Conversely, nuclear HBx was detected more frequently in tumors than in nontumorous tissue (52.1% vs. 30.3%, p < .001). HCCs expressing HBsAg, HBcAg, or cytoplasmic HBx had smaller size; lower Edmondson-Steiner (ES) nuclear grade, pT stage, and serum alpha-fetoprotein, and less angioinvasion than HCCs not expressing HBV-associated proteins. Exceptionally, nuclear HBx-positive HCCs showed higher ES nuclear grade and more frequent large-vessel invasion than did nuclear HBx-negative HCCs. In survival analysis, only nuclear HBx-positive HCCs had shorter disease-free survival than nuclear HBx-negative HCCs in pT1 and ES nuclear grade 1–2 HCC subgroup (median, 126 months vs. 35 months; p = .015).
Conclusions
Our data confirmed that expression of normal HBV-associated proteins generally decreases in tumor cells in comparison to nontumorous hepatocytes, with the exception of nuclear HBx, which suggests that nuclear HBx plays a role in recurrence of well-differentiated and early-stage HCCs.

Citations

Citations to this article as recorded by  
  • Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients
    Wei Teng, Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Su
    Cancers.2021; 13(7): 1729.     CrossRef
  • Suppression of hepatitis b virus by a combined activity of CRISPR/Cas9 and HBx proteins
    S. A. Brezgin, A. P. Kostyusheva, V. N. Simirsky, E. V. Volchkova, D. S. Chistyakov, D. S. Kostyushev, V. P. Chulanov
    Russian Journal of Infection and Immunity.2019; 9(3-4): 476.     CrossRef
  • Hepatitis B virus surface gene pre-S2mutant as a high-risk serum marker for hepatoma recurrence after curative hepatic resection
    Chia-Jui Yen, Yu-Lin Ai, Hung-Wen Tsai, Shih-Huang Chan, Chia-Sheng Yen, Kuang-Hsiung Cheng, Yun-Ping Lee, Chia-Wei Kao, Yu-Chun Wang, Yi-Lin Chen, Cheng-Han Lin, Tsunglin Liu, Huey-Pin Tsai, Jen-Ren Wang, Ih-Jen Su, Wenya Huang
    Hepatology.2018; 68(3): 815.     CrossRef
  • Integrin α6 as an invasiveness marker for hepatitis B viral X-driven hepatocellular carcinoma
    Yi Rang Kim, Mi Ran Byun, Jin Woo Choi
    Cancer Biomarkers.2018; 23(1): 135.     CrossRef
Interobserver Agreement on Pathologic Features of Liver Biopsy Tissue in Patients with Nonalcoholic Fatty Liver Disease
Eun Sun Jung, Kyoungbun Lee, Eunsil Yu, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Woo Sung Moon, Jin Sook Jeong, Cheol Keun Park, Jae-Bok Park, Dae Young Kang, Jin Hee Sohn, So-Young Jin
J Pathol Transl Med. 2016;50(3):190-196.   Published online April 18, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.01
  • 9,214 View
  • 216 Download
  • 17 Citations
AbstractAbstract PDF
Background
The histomorphologic criteria for the pathological features of liver tissue from patients with non-alcoholic fatty liver disease (NAFLD) remain subjective, causing confusion among pathologists and clinicians. In this report, we studied interobserver agreement of NAFLD pathologic features and analyzed causes of disagreement.
Methods
Thirty-one cases of clinicopathologically diagnosed NAFLD from 10 hospitals were selected. One hematoxylin and eosin and one Masson’s trichrome-stained virtual slide from each case were blindly reviewed with regard to 12 histological parameters by 13 pathologists in a gastrointestinal study group of the Korean Society of Pathologists. After the first review, we analyzed the causes of disagreement and defined detailed morphological criteria. The glass slides from each case were reviewed a second time after a consensus meeting. The degree of interobserver agreement was determined by multi-rater kappa statistics.
Results
Kappa values of the first review ranged from 0.0091–0.7618. Acidophilic bodies (k = 0.7618) and portal inflammation (k = 0.5914) showed high levels of agreement, whereas microgranuloma (k = 0.0984) and microvesicular fatty change (k = 0.0091) showed low levels of agreement. After the second review, the kappa values of the four major pathological features increased from 0.3830 to 0.5638 for steatosis grade, from 0.1398 to 0.2815 for lobular inflammation, from 0.1923 to 0.3362 for ballooning degeneration, and from 0.3303 to 0.4664 for fibrosis.
Conclusions
More detailed histomorphological criteria must be defined for correct diagnosis and high interobserver agreement of NAFLD.

Citations

Citations to this article as recorded by  
  • Improved pathology reporting in NAFLD/NASH for clinical trials
    Caitlin Rose Langford, Marc H Goldinger, Darren Treanor, Clare McGenity, Jonathan R Dillman, Daniela S Allende, Robert Goldin, Elizabeth M Brunt, Kurt Zatloukal, Helmut Denk, Kenneth A Fleming
    Journal of Clinical Pathology.2022; 75(2): 73.     CrossRef
  • Standardizing the histological assessment of late posttransplantation biopsies from pediatric liver allograft recipients
    Stefan G. Hübscher, Sandy Feng, Annette S. H. Gouw, Hironori Haga, Hyo Jeong Kang, Deirdre A. Kelly, Mina Komuta, Andrew Lesniak, Benjamin A. Popp, Henkjan J. Verkade, Eunsil Yu, Anthony J. Demetris
    Liver Transplantation.2022; 28(9): 1475.     CrossRef
  • Discordant pathological diagnosis of non‐alcoholic fatty liver disease: A prospective multicenter study
    Takuya Kuwashiro, Hirokazu Takahashi, Hideyuki Hyogo, Yuji Ogawa, Kento Imajo, Masato Yoneda, Takashi Nakahara, Satoshi Oeda, Kenichi Tanaka, Yuichiro Amano, Shinji Ogawa, Atsushi Kawaguchi, Shinichi Aishima, Masayoshi Kage, Kazuaki Chayama, Atsushi Nakaj
    JGH Open.2020; 4(3): 497.     CrossRef
  • Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns
    Stergios A. Polyzos, Jannis Kountouras, Christos S. Mantzoros
    Metabolism.2020; 104: 154144.     CrossRef
  • A scoring system for the diagnosis of non-alcoholic steatohepatitis from liver biopsy
    Kyoungbun Lee, Eun Sun Jung, Eunsil Yu, Yun Kyung Kang, Mee-Yon Cho, Joon Mee Kim, Woo Sung Moon, Jin Sook Jeong, Cheol Keun Park, Jae-Bok Park, Dae Young Kang, Jin Hee Sohn, So-Young Jin
    Journal of Pathology and Translational Medicine.2020; 54(3): 228.     CrossRef
  • An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials
    Wei-Qiang Leow, Pierre Bedossa, Feng Liu, Lai Wei, Kiat-Hon Lim, Wei-Keat Wan, Yayun Ren, Jason Pik-Eu Chang, Chee-Kiat Tan, Aileen Wee, George Boon-Bee Goh
    Diagnostics.2020; 10(9): 643.     CrossRef
  • Deep learning quantification of percent steatosis in donor liver biopsy frozen sections
    Lulu Sun, Jon N. Marsh, Matthew K. Matlock, Ling Chen, Joseph P. Gaut, Elizabeth M. Brunt, S. Joshua Swamidass, Ta-Chiang Liu
    EBioMedicine.2020; 60: 103029.     CrossRef
  • Magnetic resonance elastography SE-EPI vs GRE sequences at 3T in a pediatric population with liver disease
    Juan S. Calle-Toro, Suraj D. Serai, Erum A. Hartung, David J. Goldberg, Bradley D. Bolster, Kassa Darge, Sudha A. Anupindi
    Abdominal Radiology.2019; 44(3): 894.     CrossRef
  • R2 relaxometry based MR imaging for estimation of liver iron content: A comparison between two methods
    Juan S. Calle-Toro, Christian A. Barrera, Dmitry Khrichenko, Hansel J. Otero, Suraj D. Serai
    Abdominal Radiology.2019; 44(9): 3058.     CrossRef
  • Inhibition of mitochondrial fatty acid oxidation in drug-induced hepatic steatosis
    Bernard Fromenty
    Liver Research.2019; 3(3-4): 157.     CrossRef
  • Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials
    Rish K. Pai, David E. Kleiner, John Hart, Oyedele A. Adeyi, Andrew D. Clouston, Cynthia A. Behling, Dhanpat Jain, Sanjay Kakar, Mayur Brahmania, Lawrence Burgart, Kenneth P. Batts, Mark A. Valasek, Michael S. Torbenson, Maha Guindi, Hanlin L. Wang, Veeral
    Alimentary Pharmacology & Therapeutics.2019; 50(10): 1100.     CrossRef
  • NAFLD Histology: a Critical Review and Comparison of Scoring Systems
    Rish K. Pai
    Current Hepatology Reports.2019; 18(4): 473.     CrossRef
  • Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis
    Michael Estep, Rohini Mehta, Gary Bratthauer, Lakshmi Alaparthi, Fanny Monge, Simon Ali, Dinan Abdelatif, Zahra Younoszai, Maria Stepanova, Zachary D. Goodman, Zobair M. Younossi
    BMC Gastroenterology.2019;[Epub]     CrossRef
  • Validation of intimate correlation between visceral fat and hepatic steatosis: Quantitative measurement techniques using CT for area of fat and MR for hepatic steatosis
    Moon Hyung Choi, Joon-Il Choi, Michael Yong Park, Sung Eun Rha, Soon Nam Oh, Seung Eun Jung, Jae Young Byun, Stephan Kannengiesser, Yohan Son
    Clinical Nutrition.2018; 37(1): 214.     CrossRef
  • Ultrasound or MR elastography of liver: which one shall I use?
    Meng Yin, Sudhakar K. Venkatesh
    Abdominal Radiology.2018; 43(7): 1546.     CrossRef
  • Feasibility and agreement of stiffness measurements using gradient-echo and spin-echo MR elastography sequences in unselected patients undergoing liver MRI
    Guilherme Moura Cunha, Kevin J Glaser, Anke Bergman, Rodrigo P Luz, Eduardo H de Figueiredo, Flavia Paiva Proença Lobo Lopes
    The British Journal of Radiology.2018; : 20180126.     CrossRef
  • Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease
    Pik Eu Chang, George Boon Bee Goh, Wei Qiang Leow, Liang Shen, Kiat Hon Lim, Chee Kiat Tan, Manlio Vinciguerra
    PLOS ONE.2018; 13(6): e0199166.     CrossRef
Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
Taebum Lee, Boram Lee, Yoon-La Choi, Joungho Han, Myung-Ju Ahn, Sang-Won Um
J Pathol Transl Med. 2016;50(3):197-203.   Published online April 18, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.09
  • 15,892 View
  • 267 Download
  • 54 Citations
AbstractAbstract PDF
Background
Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be mutually exclusive, some tumors harbor concomitant mutations. Discovering a driver mutation on the basis of morphologic features and therapeutic responses with mutation analysis can be used to understand pathogenesis and predict resistance in targeted therapy.
Methods
In 6,637 patients with NSCLC, 12 patients who had concomitant mutations were selected and clinicopathologic features were reviewed. Clinical characteristics included sex, age, smoking history, previous treatment, and targeted therapy with response and disease-free survival. Histologic features included dominant patterns, nuclear and cytoplasmic features.
Results
All patients were diagnosed with adenocarcinoma and had an EGFR mutation. Six patients had concomitant KRAS mutations and the other six had ALK mutations. Five of six EGFR-KRAS mutation patients showed papillary and acinar histologic patterns with hobnail cells. Three of six received EGFR tyrosine kinase inhibitor (TKI) and showed partial response for 7–29 months. All six EGFR-ALK mutation patients showed solid or cribriform patterns and three had signet ring cells. Five of six EGFR-ALK mutation patients received EGFR TKI and/or ALK inhibitor and four showed partial response or stable disease, except for one patient who had acquired an EGFR mutation.
Conclusions
EGFR and ALK mutations play an important role as driver mutations in double mutated NSCLC, and morphologic analysis can be used to predict treatment response.

Citations

Citations to this article as recorded by  
  • Next generation sequencing for detection of EGFR alterations in NSCLC: is more better?
    Ullas Batra, Shrinidhi Nathany, Mansi Sharma, Parveen Jain, Anurag Mehta
    Journal of Clinical Pathology.2022; 75(3): 164.     CrossRef
  • Enkurin domain containing 1 (ENKD1) regulates the proliferation, migration and invasion of non‐small cell lung cancer cells
    Ting Song, Peng Zhou, Chunjiao Sun, Na He, Haixia Li, Jie Ran, Jun Zhou, Yue Wu, Min Liu
    Asia-Pacific Journal of Clinical Oncology.2022;[Epub]     CrossRef
  • Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
    Jia-Xin Li, Run-Ze Li, Lin-Rui Ma, Peng Wang, Dong-Han Xu, Jie Huang, Li-Qi Li, Ling Tang, Ying Xie, Elaine Lai-Han Leung, Pei-Yu Yan
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Histone H3K9 methyltransferase SETDB1 augments invadopodia formation to promote tumor metastasis
    Shuhei Ueshima, Jia Fang
    Oncogene.2022; 41(24): 3370.     CrossRef
  • ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
    A. Passaro, N. Leighl, F. Blackhall, S. Popat, K. Kerr, M.J. Ahn, M.E. Arcila, O. Arrieta, D. Planchard, F. de Marinis, A.M. Dingemans, R. Dziadziuszko, C. Faivre-Finn, J. Feldman, E. Felip, G. Curigliano, R. Herbst, P.A. Jänne, T. John, T. Mitsudomi, T.
    Annals of Oncology.2022; 33(5): 466.     CrossRef
  • Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
    Begoña O. Alen, Lara S. Estévez-Pérez, María Teresa Hermida-Romero, Ana Reguera-Arias, Rosario García-Campelo, Mercedes de la Torre-Bravos, Ángel Concha
    Cancers.2022; 14(14): 3323.     CrossRef
  • Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer
    Yock Ping Chow, Norziha Zainul Abidin, Ken Siong Kow, Lye Mun Tho, Chieh Lee Wong, Rama Krishna Kancha
    PLOS ONE.2022; 17(10): e0276161.     CrossRef
  • Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors
    Ming-Hung Huang, Jih-Hsiang Lee, Pei-Shan Hung, James Chih-Hsin Yang
    JTO Clinical and Research Reports.2022; 3(11): 100405.     CrossRef
  • Artificial Intelligence in Lung Cancer Imaging: Unfolding the Future
    Michaela Cellina, Maurizio Cè, Giovanni Irmici, Velio Ascenti, Natallia Khenkina, Marco Toto-Brocchi, Carlo Martinenghi, Sergio Papa, Gianpaolo Carrafiello
    Diagnostics.2022; 12(11): 2644.     CrossRef
  • A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Yanxia Liu, Yuan Gao, Ying Wang, Cong Zhao, Zhiyun Zhang, Baolan Li, Tongmei Zhang
    BMC Cancer.2022;[Epub]     CrossRef
  • High frequency of KRAS and EGFR mutation profiles in BRAF-negative thyroid carcinomas in Indonesia
    Didik Setyo Heriyanto, Vincent Laiman, Nikko Vanda Limantara, Widyan Putra Anantawikrama, Fara Silvia Yuliani, Rita Cempaka, Sumadi Lukman Anwar
    BMC Research Notes.2022;[Epub]     CrossRef
  • Targeted next-generation sequencing for cancer-associated gene mutation and copy number detection in 206 patients with non–small-cell lung cancer
    Songbai Zheng, Xiaodan Wang, Ying Fu, Beibei Li, Jianhua Xu, Haifang Wang, Zhen Huang, Hui Xu, Yurong Qiu, Yaozhou Shi, Kui Li
    Bioengineered.2021; 12(1): 791.     CrossRef
  • How mathematical modeling could contribute to the quantification of metastatic tumor burden under therapy: insights in immunotherapeutic treatment of non-small cell lung cancer
    Pirmin Schlicke, Christina Kuttler, Christian Schumann
    Theoretical Biology and Medical Modelling.2021;[Epub]     CrossRef
  • A case of concomitant EGFR/ALK alteration against a mutated EGFR background in early-stage lung adenocarcinoma
    Ki-Chang Lee, Jiwon Koh, Doo Hyun Chung, Yoon Kyung Jeon
    Journal of Pathology and Translational Medicine.2021; 55(2): 139.     CrossRef
  • Malfeasance of KRAS mutations in carcinogenesis
    Rupal Tripathi, Shrinidhi Nathany, Anurag Mehta, Ullas Batra, Sakshi Mattoo, Mansi Sharma
    Clinical and Experimental Medicine.2021; 21(3): 439.     CrossRef
  • Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
    Giorgia Nardo, Jessica Carlet, Ludovica Marra, Laura Bonanno, Alice Boscolo, Alessandro Dal Maso, Andrea Boscolo Bragadin, Stefano Indraccolo, Elisabetta Zulato
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma
    Valerio Gristina, Maria La Mantia, Antonio Galvano, Sofia Cutaia, Nadia Barraco, Marta Castiglia, Alessandro Perez, Marco Bono, Federica Iacono, Martina Greco, Katia Calcara, Valentina Calò, Sergio Rizzo, Lorena Incorvaia, Maria Chiara Lisanti, Giulia San
    Journal of Molecular Pathology.2021; 2(2): 173.     CrossRef
  • Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets
    Mercedes L Dalurzo, Alejandro Avilés-Salas, Fernando Augusto Soares, Yingyong Hou, Yuan Li, Anna Stroganova, Büge Öz, Arif Abdillah, Hui Wan, Yoon-La Choi
    OncoTargets and Therapy.2021; Volume 14: 4671.     CrossRef
  • Untangling the KRAS mutated lung cancer subsets and its therapeutic implications
    Kulshrestha Ritu, Pawan Kumar, Amit Singh, K. Nupur, Sonam Spalgias, Parul Mrigpuri, Rajkumar
    Molecular Biomedicine.2021;[Epub]     CrossRef
  • Lorlatinib Induces Durable Disease Stabilization in a Pancreatic Cancer Patient with a ROS1 p.L1950F Mutation: Case Report
    Janna-Lisa Velthaus, Peter Iglauer, Ronald Simon, Carsten Bokemeyer, Peter Bannas, Niklas Beumer, Charles D. Imbusch, Eray Goekkurt, Sonja Loges
    Oncology Research and Treatment.2021; 44(9): 495.     CrossRef
  • Proteasome-dependent degradation of Smad7 is critical for lung cancer metastasis
    Lu Tong, Shihui Shen, Quan Huang, Junjiang Fu, Tianzhen Wang, Linian Pan, Pei Zhang, Geng Chen, Tingmei Huang, Ke Li, Qingwu Liu, Shaofang Xie, Xiao Yang, Robb E. Moses, Xiaotao Li, Lei Li
    Cell Death & Differentiation.2020; 27(6): 1795.     CrossRef
  • Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis
    Zhoumiao Chen, Huiwen Miao, Qingxin Zeng, Shaohua Xu, Zhao Chen, Kai Liu
    Biomarkers in Medicine.2020; 14(7): 587.     CrossRef
  • Influence of EGFR-activating mutations on sensitivity to tyrosine kinase inhibitors in a KRAS mutant non-small cell lung cancer cell line
    Yoshinori Tsukumo, Mikihiko Naito, Takayoshi Suzuki, Srikumar Chellappan
    PLOS ONE.2020; 15(3): e0229712.     CrossRef
  • KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC )
    Hanxiao Chen, Jun Zhao
    Thoracic Cancer.2020; 11(12): 3425.     CrossRef
  • Epidemiologic Features of NSCLC Gene Alterations in Hispanic Patients from Puerto Rico
    Ruifang Zheng, Zhiwei Yin, Albert Alhatem, Derek Lyle, Bei You, Andrew S. Jiang, Dongfang Liu, Zsolt Jobbagy, Qing Wang, Seena Aisner, Jie-Gen Jiang
    Cancers.2020; 12(12): 3492.     CrossRef
  • Comprehensive pancancer genomic analysis reveals (RTK)-RAS-RAF-MEK as a key dysregulated pathway in cancer: Its clinical implications
    Robin Imperial, Omer M Toor, Arif Hussain, Janakiraman Subramanian, Ashiq Masood
    Seminars in Cancer Biology.2019; 54: 14.     CrossRef
  • Epidermal growth factor receptor (EGFR), KRAS, and BRAF mutations in lung adenocarcinomas: A study from India
    Varsha Singh, Prerna Guleria, Prabhat Singh Malik, Anant Mohan, Sanjay Thulkar, R M Pandey, Kalpana Luthra, Sudheer Arava, Ruma Ray, Deepali Jain
    Current Problems in Cancer.2019; 43(5): 391.     CrossRef
  • Clinical Validation of Coexisting Activating Mutations Within EGFR, Mitogen-Activated Protein Kinase, and Phosphatidylinositol 3-Kinase Pathways in Lung Cancers
    Federico De Marchi, Lisa Haley, Henderson Fryer, Junaid Ibrahim, Katie Beierl, Gang Zheng, Christopher D. Gocke, James R. Eshleman, Deborah Belchis, Peter Illei, Ming-Tseh Lin
    Archives of Pathology & Laboratory Medicine.2019; 143(2): 174.     CrossRef
  • A sequential Monte Carlo algorithm for inference of subclonal structure in cancer
    Oyetunji E. Ogundijo, Kaiyi Zhu, Xiaodong Wang, Dimitris Anastassiou, Xiang Li
    PLOS ONE.2019; 14(1): e0211213.     CrossRef
  • The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
    Anna Rachiglio, Francesca Fenizia, Maria Piccirillo, Domenico Galetta, Lucio Crinò, Bruno Vincenzi, Emiddio Barletta, Carmine Pinto, Francesco Ferraù, Matilde Lambiase, Agnese Montanino, Cristin Roma, Vienna Ludovini, Elisabetta Montagna, Antonella De Luc
    Cancers.2019; 11(3): 341.     CrossRef
  • Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
    Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Li Zhang, Yalan Bi, Mengzhao Wang
    EBioMedicine.2019; 42: 304.     CrossRef
  • Anaplastic Lymphoma Kinase (ALK)-positive Tumors
    Rohan Gupta, Idoroenyi Amanam, Syed Rahmanuddin, Isa Mambetsariev, Yingyu Wang, Charity Huang, Karen Reckamp, Lalit Vora, Ravi Salgia
    American Journal of Clinical Oncology.2019; 42(4): 337.     CrossRef
  • Clinical features and therapeutic options in non‐small cell lung cancer patients with concomitant mutations of EGFR , ALK , ROS1 , KRAS or
    Xibin Zhuang, Chao Zhao, Jiayu Li, Chunxia Su, Xiaoxia Chen, Shengxiang Ren, Xuefei Li, Caicun Zhou
    Cancer Medicine.2019; 8(6): 2858.     CrossRef
  • Intrinsic resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
    Santoni-Rugiu, Melchior, Urbanska, Jakobsen, Stricker, Grauslund, Sørensen
    Cancers.2019; 11(7): 923.     CrossRef
  • Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation
    J. Chantharasamee, N. Poungvarin, P. Danchaivijitr, S. Techawatanawanna
    BMC Cancer.2019;[Epub]     CrossRef
  • Deregulated lncRNA expression profile in the mouse lung adenocarcinomas with KRAS‐G12D mutation and P53 knockout
    Meiqin Zhang, Nan Jiang, Renjie Cui, Sichen Du, Huayuan Ou, Tinglan Chen, Runsheng Ge, Duan Ma, Jin Zhang
    Journal of Cellular and Molecular Medicine.2019; 23(10): 6978.     CrossRef
  • Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes
    Erica K. Barnell, Adam Waalkes, Matt C. Mosior, Kelsi Penewit, Kelsy C. Cotto, Arpad M. Danos, Lana M. Sheta, Katie M. Campbell, Kilannin Krysiak, Damian Rieke, Nicholas C. Spies, Zachary L. Skidmore, Colin C. Pritchard, Todd A. Fehniger, Ravindra Uppalur
    JCO Clinical Cancer Informatics.2019; (3): 1.     CrossRef
  • EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma
    Maria Colombino, Panagiotis Paliogiannis, Antonio Cossu, Davide Adriano Santeufemia, Maria Cristina Sini, Milena Casula, Grazia Palomba, Antonella Manca, Marina Pisano, Valentina Doneddu, Giuseppe Palmieri
    BMC Pulmonary Medicine.2019;[Epub]     CrossRef
  • Concomitant Presence of EGFR and ALK Fusion Gene Mutation in Adenocarcinoma of Lung: A Case Report and Review of the Literature
    Nishitha Thumallapally, Hana Yu, Mohammad Farhan, Uroosa Ibrahim, Maricel Odiami
    Journal of Pharmacy Practice.2018; 31(2): 244.     CrossRef
  • Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC
    Nele Van Der Steen, Yves Mentens, Marc Ramael, Leticia G. Leon, Paul Germonpré, Jose Ferri, David R. Gandara, Elisa Giovannetti, Godefridus J. Peters, Patrick Pauwels, Christian Rolfo
    Clinical Lung Cancer.2018; 19(1): 35.     CrossRef
  • KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
    Marta Román, Iosune Baraibar, Inés López, Ernest Nadal, Christian Rolfo, Silvestre Vicent, Ignacio Gil-Bazo
    Molecular Cancer.2018;[Epub]     CrossRef
  • Pulmonary Adenocarcinoma, Harboring Both an EGFR Mutation and ALK Rearrangement, Presenting a Stable Disease to Erlotinib and a Partial Response to Alectinib
    Akira Yokoyama, Atsuhisa Tamura, Kazuko Miyakawa, Kei Kusaka, Masahiro Shimada, Takashi Hirose, Hirotoshi Matsui, Masashi Kitani, Akira Hebisawa, Ken Ohta
    Internal Medicine.2018; 57(16): 2377.     CrossRef
  • Long-term survival with erlotinib in advanced lung adenocarcinoma harboring synchronous EGFR G719S and KRAS G12C mutations
    Biagio Ricciuti, Sara Baglivo, Vienna Ludovini, Angelo Sidoni, Giulio Metro, Marta Brambilla, Annamaria Siggillino, Maria Sole Reda, Alberto Rebonato, Daniele Maiettini, Rita Chiari
    Lung Cancer.2018; 120: 70.     CrossRef
  • Concomitant driver mutations in advanced EGFR-mutated non-small-cell lung cancer and their impact on erlotinib treatment
    Jan Nyrop Jakobsen, Eric Santoni-Rugiu, Morten Grauslund, Linea Melchior, Jens Benn Sørensen
    Oncotarget.2018; 9(40): 26195.     CrossRef
  • Implications of KRAS mutations in acquired resistance to treatment in NSCLC
    Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini, Romano Danesi
    Oncotarget.2018; 9(5): 6630.     CrossRef
  • Alk Immunohistochemistry is Highly Sensitive and Specific for the Detection of Alk Translocated Lung Adenocarcinomas: Lessons from An Audit of Lung Cancer Molecular Testing
    YC Kheng, K Walsh, L Williams, WA Wallace, DJ Harrison, A Oniscu
    Journal of the Royal College of Physicians of Edinburgh.2018; 48(1): 20.     CrossRef
  • Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity
    Alexios Matikas, Dimitrios Mistriotis, Vasilios Georgoulias, Athanasios Kotsakis
    Critical Reviews in Oncology/Hematology.2017; 110: 1.     CrossRef
  • Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)
    Sabine Schmid, Oliver Gautschi, Sacha Rothschild, Michael Mark, Patrizia Froesch, Dirk Klingbiel, Hermann Reichegger, Wolfram Jochum, Joachim Diebold, Martin Früh
    Journal of Thoracic Oncology.2017; 12(4): 681.     CrossRef
  • EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology
    Vincent Thomas De Montpréville, Maria-Rosa Ghigna, Ludovic Lacroix, Antoinette Lemoine, Benjamin Besse, Olaf Mercier, Élie Fadel, Peter Dorfmuller, Thierry Le Chevalier
    Pathology - Research and Practice.2017; 213(7): 793.     CrossRef
  • MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values
    Geun Dong Lee, Seung Eun Lee, Doo-Yi Oh, Dan-bi Yu, Hae Min Jeong, Jooseok Kim, Sungyoul Hong, Hun Soon Jung, Ensel Oh, Ji-Young Song, Mi-Sook Lee, Mingi Kim, Kyungsoo Jung, Jhingook Kim, Young Kee Shin, Yoon-La Choi, Hyeong Ryul Kim
    Journal of Thoracic Oncology.2017; 12(8): 1233.     CrossRef
  • Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)
    Jean-Bernard Auliac, Isabelle Monnet, Catherine Dubos-Arvis, Anne Marie Chiappa, Nathalie Baize, Suzana Bota, Alain Vergnenegre, Helene Doubre, Chrystele Locher, Acya Bizieux, Gilles Robinet, Christos Chouaid
    Targeted Oncology.2017; 12(6): 833.     CrossRef
  • Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases
    Giuseppe Lo Russo, Martina Imbimbo, Giulia Corrao, Claudia Proto, Diego Signorelli, Milena Vitali, Monica Ganzinelli, Laura Botta, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino
    Oncotarget.2017; 8(35): 59889.     CrossRef
  • Management of non-small cell lung cancer in the era of personalized medicine
    Gaetano Rocco, Alessandro Morabito, Alessandra Leone, Paolo Muto, Francesco Fiore, Alfredo Budillon
    The International Journal of Biochemistry & Cell Biology.2016; 78: 173.     CrossRef
  • A long-term survivor of non-small-cell lung cancer harboring concomitant EGFR mutation and ALK translocation
    Fumio Imamura, Takako Inoue, Madoka Kimura, Kazumi Nishino, Toru Kumagai
    Respiratory Medicine Case Reports.2016; 19: 137.     CrossRef
Analysis of Surgical Pathology Data in the HIRA Database: Emphasis on Current Status and Endoscopic Submucosal Dissection Specimens
Sun-ju Byeon, Woo Ho Kim
J Pathol Transl Med. 2016;50(3):204-210.   Published online April 4, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.04
  • 7,024 View
  • 66 Download
  • 2 Citations
AbstractAbstract PDF
Background
In Korea, medical institutions make claims for insurance reimbursement to the Health Insurance Review and Assessment Service (HIRA). Thus, HIRA databases reflect the general medical services that are provided in Korea. We conducted two pathology-related studies using a HIRA national patient sample (NPS) data (selection probability, 0.03). First, we evaluated the current status of general pathologic examination in Korea. Second, we evaluated pathologic issues associated with endoscopic submucosal dissection (ESD).
Methods
The sample data used in this study was HIRA-NPS-2013-0094.
Results
In the NPS dataset, 163,372 pathologic examinations were performed in 103,528 patients during the year 2013. Considering sampling weight (33.3), it is estimated that 5,440,288 (163,372 × 33.3) pathologic examinations were performed. Internal medicine and general surgery were the most common departments requesting pathologic examinations. The region performing pathologic examinations were different according to type of medical institution. In total, 490 patients underwent ESD, and 43.4% (213/490) underwent ESD due to gastric carcinoma. The results of the ESD led to a change in disease code for 10.5% (29/277) of non-gastric carcinoma patients. In addition, 21 patients (4.3%) underwent surgery following the ESD. The average period between ESD and surgery was 44 days.
Conclusions
HIRA sample data provide the nation-wide landscape of specific procedure. However, in order to reduce the statistical error, further studies using entire HIRA data are needed.

Citations

Citations to this article as recorded by  
  • Using big data to see the forest and the trees: endoscopic submucosal dissection of early gastric cancer in Korea
    Chang Seok Bang, Gwang Ho Baik
    The Korean Journal of Internal Medicine.2019; 34(4): 772.     CrossRef
  • Current Status of Pathologic Examinations in Korea, 2011–2015, Based on the Health Insurance Review and Assessment Service Dataset
    Sun-ju Byeon
    Journal of Pathology and Translational Medicine.2017; 51(2): 137.     CrossRef
Aberrant Blood Vessel Formation Connecting the Glomerular Capillary Tuft and the Interstitium Is a Characteristic Feature of Focal Segmental Glomerulosclerosis-like IgA Nephropathy
Beom Jin Lim, Min Ju Kim, Soon Won Hong, Hyeon Joo Jeong
J Pathol Transl Med. 2016;50(3):211-216.   Published online April 11, 2016
DOI: https://doi.org/10.4132/jptm.2016.02.01
  • 6,483 View
  • 63 Download
  • 1 Citations
AbstractAbstract PDF
Background
Segmental glomerulosclerosis without significant mesangial or endocapillary proliferation is rarely seen in IgA nephropathy (IgAN), which simulates idiopathic focal segmental glomerulosclerosis (FSGS). We recently recognized aberrant blood vessels running through the adhesion sites of sclerosed tufts and Bowman’s capsule in IgAN cases with mild glomerular histologic change.
Methods
To characterize aberrant blood vessels in relation to segmental sclerosis, we retrospectively reviewed the clinical and histologic features of 51 cases of FSGS-like IgAN and compared them with 51 age and gender-matched idiopathic FSGS cases.
Results
In FSGS-like IgAN, aberrant blood vessel formation was observed in 15.7% of cases, 1.0% of the total glomeruli, and 7.3% of the segmentally sclerosed glomeruli, significantly more frequently than in the idiopathic FSGS cases (p = .009). Aberrant blood vessels occasionally accompanied mild cellular proliferation surrounding penetrating neovessels. Clinically, all FSGS-like IgAN cases had hematuria; however, nephrotic range proteinuria was significantly less frequent than idiopathic FSGS.
Conclusions
Aberrant blood vessels in IgAN are related to glomerular capillary injury and may indicate abnormal repair processes in IgAN.

Citations

Citations to this article as recorded by  
  • IgA nephropathy
    Maria F. Soares, Ian S.D. Roberts
    Current Opinion in Nephrology and Hypertension.2017; 26(3): 165.     CrossRef
Core Needle Biopsy Is a More Conclusive Follow-up Method Than Repeat Fine Needle Aspiration for Thyroid Nodules with Initially Inconclusive Results: A Systematic Review and Meta-Analysis
Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang
J Pathol Transl Med. 2016;50(3):217-224.   Published online April 14, 2016
DOI: https://doi.org/10.4132/jptm.2016.02.15
  • 8,567 View
  • 98 Download
  • 17 Citations
AbstractAbstract PDF
Background
This study investigated the appropriate management of thyroid nodules with prior non-diagnostic or atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) through a systematic review and meta-analysis.
Methods
This study included 4,235 thyroid nodules from 26 eligible studies. We investigated the conclusive rate of follow-up core needle biopsy (CNB) or repeat fine needle aspiration (rFNA) after initial fine needle aspiration (FNA) with non-diagnostic or AUS/FLUS results. A diagnostic test accuracy (DTA) review was performed to determine the diagnostic role of the follow-up CNB and to calculate the area under the curve (AUC) on the summary receiver operating characteristic (SROC) curve.
Results
The conclusive rates of follow-up CNB and rFNA after initial FNA were 0.879 (95% confidence interval [CI], 0.801 to 0.929) and 0.684 (95% CI, 0.627 to 0.736), respectively. In comparison of the odds ratios of CNB and rFNA, CNB had more frequent conclusive results than rFNA (odds ratio, 5.707; 95% CI, 2.530 to 12.875). Upon subgroup analysis, follow-up CNB showed a higher conclusive rate than rFNA in both initial non-diagnostic and AUS/FLUS subgroups. In DTA review of followup CNB, the pooled sensitivity and specificity were 0.94 (95% CI, 0.88 to 0.97) and 0.88 (95% CI, 0.84 to 0.91), respectively. The AUC for the SROC curve was 0.981, nearing 1.
Conclusions
Our results show that CNB has a higher conclusive rate than rFNA when the initial FNA produced inconclusive results. Further prospective studies with more detailed criteria are necessary before follow-up CNB can be applied in daily practice.

Citations

Citations to this article as recorded by  
  • Fine Needle Aspiration Cytology vs. Core Needle Biopsy for Thyroid Nodules: A Prospective, Experimental Study Using Surgical Specimen
    Hyuk Kwon, Jandee Lee, Soon Won Hong, Hyeong Ju Kwon, Jin Young Kwak, Jung Hyun Yoon
    Journal of the Korean Society of Radiology.2022; 83(3): 645.     CrossRef
  • Comparison of Core Needle Biopsy and Repeat Fine-Needle Aspiration in Avoiding Diagnostic Surgery for Thyroid Nodules Initially Diagnosed as Atypia/Follicular Lesion of Undetermined Significance
    Leehi Joo, Dong Gyu Na, Ji-hoon Kim, Hyobin Seo
    Korean Journal of Radiology.2022; 23(2): 280.     CrossRef
  • Diagnostic performance of core needle biopsy as a first‐line diagnostic tool for thyroid nodules according to ultrasound patterns: Comparison with fine needle aspiration using propensity score matching analysis
    Hye Shin Ahn, Inyoung Youn, Dong Gyu Na, Soo Jin Kim, Mi Yeon Lee
    Clinical Endocrinology.2021; 94(3): 494.     CrossRef
  • Usage and Diagnostic Yield of Fine-Needle Aspiration Cytology and Core Needle Biopsy in Thyroid Nodules: A Systematic Review and Meta-Analysis of Literature Published by Korean Authors
    Soon-Hyun Ahn
    Clinical and Experimental Otorhinolaryngology.2021; 14(1): 116.     CrossRef
  • 2021 Korean Thyroid Imaging Reporting and Data System and Imaging-Based Management of Thyroid Nodules: Korean Society of Thyroid Radiology Consensus Statement and Recommendations
    Eun Ju Ha, Sae Rom Chung, Dong Gyu Na, Hye Shin Ahn, Jin Chung, Ji Ye Lee, Jeong Seon Park, Roh-Eul Yoo, Jung Hwan Baek, Sun Mi Baek, Seong Whi Cho, Yoon Jung Choi, Soo Yeon Hahn, So Lyung Jung, Ji-hoon Kim, Seul Kee Kim, Soo Jin Kim, Chang Yoon Lee, Ho K
    Korean Journal of Radiology.2021; 22(12): 2094.     CrossRef
  • Malignancy rate of Bethesda category III thyroid nodules according to ultrasound risk stratification system and cytological subtype
    Won Sang Yoo, Hwa Young Ahn, Hye Shin Ahn, Yun Jae Chung, Hee Sung Kim, Bo Youn Cho, Mirinae Seo, Jae Hoon Moon, Young Joo Park
    Medicine.2020; 99(2): e18780.     CrossRef
  • 2019 Practice guidelines for thyroid core needle biopsy: a report of the Clinical Practice Guidelines Development Committee of the Korean Thyroid Association
    Chan Kwon Jung, Jung Hwan Baek, Dong Gyu Na, Young Lyun Oh, Ka Hee Yi, Ho-Cheol Kang
    Journal of Pathology and Translational Medicine.2020; 54(1): 64.     CrossRef
  • Laser Ablation Versus Radiofrequency Ablation for Benign Non-Functioning Thyroid Nodules: Six-Month Results of a Randomized, Parallel, Open-Label, Trial (LARA Trial)
    Roberto Cesareo, Claudio Maurizio Pacella, Valerio Pasqualini, Giuseppe Campagna, Mario Iozzino, Andrea Gallo, Angelo Lauria Pantano, Roberto Cianni, Claudio Pedone, Paolo Pozzilli, Chiara Taffon, Anna Crescenzi, Silvia Manfrini, Andrea Palermo
    Thyroid.2020; 30(6): 847.     CrossRef
  • Diagnostic Efficacy and Safety of Core Needle Biopsy as a First-Line Diagnostic Method for Thyroid Nodules: A Prospective Cohort Study
    Min Ji Hong, Dong Gyu Na, Hunkyung Lee
    Thyroid.2020; 30(8): 1141.     CrossRef
  • Is thyroid core needle biopsy a valid compliment to fine-needle aspiration?
    Liron Pantanowitz, Lester D.R. Thompson, Xin Jing, Esther Diana Rossi
    Journal of the American Society of Cytopathology.2020; 9(5): 383.     CrossRef
  • A Monocentric Retrospective Study about the Correlation between Histology and Cytology of Thyroid Indeterminate Nodules Classified as TIR 3A and TIR 3B, according to 2014 Italian Consensus for Classification and Reporting of Thyroid Cytology
    Francesco Quaglino, Giulia Arnulfo, Sergio Sandrucci, Claudio Rossi, Valentina Marchese, Roberto Saracco, Stefano Guzzetti, Stefano Taraglio, Enrico Mazza
    Advances in Medicine.2019; 2019: 1.     CrossRef
  • Nuclear features of papillary thyroid carcinoma: Comparison of Core needle biopsy and thyroidectomy specimens
    Jae Yeon Seok, Jungsuk An, Hyun Yee Cho, Younghye Kim, Seung Yeon Ha
    Annals of Diagnostic Pathology.2018; 32: 35.     CrossRef
  • Statement and Recommendations on Interventional Ultrasound as a Thyroid Diagnostic and Treatment Procedure
    Christoph F. Dietrich, Thomas Müller, Jörg Bojunga, Yi Dong, Giovanni Mauri, Maija Radzina, Manjiri Dighe, Xin-Wu Cui, Frank Grünwald, Andreas Schuler, Andre Ignee, Huedayi Korkusuz
    Ultrasound in Medicine & Biology.2018; 44(1): 14.     CrossRef
  • Role of core needle biopsy as a first-line diagnostic tool for thyroid nodules: a retrospective cohort study
    Min Ji Hong, Dong Gyu Na, Soo Jin Kim, Dae Sik Kim
    Ultrasonography.2018; 37(3): 244.     CrossRef
  • Core Needle Biopsy of the Thyroid: 2016 Consensus Statement and Recommendations from Korean Society of Thyroid Radiology
    Dong Gyu Na, Jung Hwan Baek, So Lyung Jung, Ji-hoon Kim, Jin Yong Sung, Kyu Sun Kim, Jeong Hyun Lee, Jung Hee Shin, Yoon Jung Choi, Eun Ju Ha, Hyun Kyung Lim, Soo Jin Kim, Soo Yeon Hahn, Kwang Hwi Lee, Young Jun Choi, Inyoung Youn, Young Joong Kim, Hye Sh
    Korean Journal of Radiology.2017; 18(1): 217.     CrossRef
  • Ultrasound-guided fine needle aspiration versus core needle biopsy: comparison of post-biopsy hematoma rates and risk factors
    In Hye Chae, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Vivian Y. Park, Jin Young Kwak
    Endocrine.2017; 57(1): 108.     CrossRef
  • The Role of Core Needle Biopsy for Thyroid Nodules with Initially Indeterminate Results on Previous Fine-Needle Aspiration: A Systematic Review and Meta-Analysis
    C.H. Suh, J.H. Baek, C. Park, Y.J. Choi, J.H. Lee
    American Journal of Neuroradiology.2017; 38(7): 1421.     CrossRef
Investigation of the Roles of Cyclooxygenase-2 and Galectin-3 Expression in the Pathogenesis of Premenopausal Endometrial Polyps
Esin Kasap, Serap Karaarslan, Esra Bahar Gur, Mine Genc, Nur Sahin, Serkan Güclü
J Pathol Transl Med. 2016;50(3):225-230.   Published online April 16, 2016
DOI: https://doi.org/10.4132/jptm.2016.03.08
  • 6,309 View
  • 79 Download
  • 2 Citations
AbstractAbstract PDF
Background
The pathogenesis and etiology of endometrial polyps has not been elucidated. In this study, we aimed to examine the pathogenic mechanisms of endometrial polyp development using immunohistochemistry. We evaluated the expression of galectin-3 and cyclooxgenase-2 (COX-2) during the menstrual cycle in premenopausal women with endometrial polyps or normal endometrium.
Methods
Thirty-one patients with endometrial polyps and 50 healthy control patients were included in this study. The levels of expression of COX-2 and galectin-3 were studied by immunohistochemistry.
Results
The percentage of COX-2–positive cells and the intensity of COX-2 staining in the endometrium did not vary during the menstrual cycle either in the control group or in patients with endometrial polyps. However, expression of galectin-3 was significantly lower in endometrial polyps and during the proliferative phase of the endometrium compared with the secretory phase.
Conclusions
Our data suggests that the pathogenesis of endometrial polyps does not involve expression of COX-2 or galectin-3.

Citations

Citations to this article as recorded by  
  • Novel microarchitecture of human endometrial glands: implications in endometrial regeneration and pathologies
    Nicola Tempest, Christopher J Hill, Alison Maclean, Kathleen Marston, Simon G Powell, Hannan Al-Lamee, Dharani K Hapangama
    Human Reproduction Update.2022; 28(2): 153.     CrossRef
  • Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
    Marcin Oplawski, Konrad Dziobek, Nikola Zmarzły, Beniamin O. Grabarek, Robert Kiełbasiński, Przemysław Kieszkowski, Piotr Januszyk, Karol Talkowski, Michał Schweizer, Piotr Kras, Andrzej Plewka, Dariusz Boroń
    Current Pharmaceutical Biotechnology.2020; 21(1): 52.     CrossRef
Case Studies
Rare Case of Anal Canal Signet Ring Cell Carcinoma Associated with Perianal and Vulvar Pagetoid Spread
Na Rae Kim, Hyun Yee Cho, Jeong-Heum Baek, Juhyeon Jeong, Seung Yeon Ha, Jae Yeon Seok, Sung Won Park, Sun Jin Sym, Kyu Chan Lee, Dong Hae Chung
J Pathol Transl Med. 2016;50(3):231-237.   Published online October 8, 2015
DOI: https://doi.org/10.4132/jptm.2015.08.08
  • 10,088 View
  • 107 Download
  • 2 Citations
AbstractAbstract PDF
A 61-year-old woman was referred to surgery for incidentally found colonic polyps during a health examination. Physical examination revealed widespread eczematous skin lesion without pruritus in the perianal and vulvar area. Abdominopelvic computed tomography showed an approximately 4-cm-sized, soft tissue lesion in the right perianal area. Inguinal lymph node dissection and Mils’ operation extended to perianal and perivulvar skin was performed. Histologically, the anal canal lesion was composed of mucin-containing signet ring cells, which were similar to those found in Pagetoid skin lesions. It was diagnosed as an anal canal signet ring cell carcinoma (SRCC) with perianal and vulvar Pagetoid spread and bilateral inguinal lymph node metastasis. Anal canal SRCC is rare, and the current case is the third reported case in the English literature. Seven additional cases were retrieved from the world literature. Here, we describe this rare case of anal canal SRCC with perianal Pagetoid spread and provide a literature review.

Citations

Citations to this article as recorded by  
  • Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report
    Masamichi Yamaura, Takeshi Yamada, Rei Watanabe, Hitomi Kawai, Suguru Hirose, Hiroki Tajima, Masashi Sato, Yuichi Uchida, Daisuke Suganuma, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichinosuke Hyodo
    BMC Cancer.2018;[Epub]     CrossRef
  • Solitary left axillary lymph node metastasis after curative resection of carcinoma at the colostomy site: a case report
    Ken Imaizumi, Shigenori Homma, Tadashi Yoshida, Tatsushi Shimokuni, Hideyasu Sakihama, Norihiko Takahashi, Hideki Kawamura, Emi Takakuwa, Akinobu Taketomi
    Surgical Case Reports.2016;[Epub]     CrossRef
Sclerosing Perivascular Epithelioid Cell Tumor of the Lung: A Case Report with Cytologic Findings
Ha Yeon Kim, Jin Hyuk Choi, Hye Seung Lee, Yoo Jin Choi, Aeree Kim, Han Kyeom Kim
J Pathol Transl Med. 2016;50(3):238-242.   Published online April 11, 2016
DOI: https://doi.org/10.4132/jptm.2016.02.19
  • 7,241 View
  • 92 Download
  • 6 Citations
AbstractAbstract PDF
Benign perivascular epithelioid cell tumor (PEComa) of the lung is a rare benign neoplasm, a sclerosing variant of which is even rarer. We present a case of 51-year-old man who was diagnosed with benign sclerosing PEComa by percutaneous fine needle aspiration cytology and biopsy. The aspirate revealed a few cell clusters composed of bland-looking polygonal or spindle cells with fine granular or clear cytoplasm. Occasional fine vessel-like structures with surrounding hyalinized materials were seen. The patient later underwent wedge resection of the lung. The histopathological study of the resected specimen revealed sheets of polygonal cells with clear vacuolated cytoplasm, variably sized thin blood vessels, and densely hyalinized stroma. In immunohistochemical studies, reactivity of tumor cells for human melanoma black 45 and Melan-A further supported the diagnosis of benign sclerosing PEComa. To the best of our knowledge, this is the first case of benign sclerosing PEComa described in lung.

Citations

Citations to this article as recorded by  
  • Cytopathology of rare gastric mesenchymal neoplasms: A series of 25 cases and review of literature
    Carla Saoud, Peter B. Illei, Momin T. Siddiqui, Syed Z. Ali
    Cytopathology.2023; 34(1): 15.     CrossRef
  • Retroperitoneal Sclerosing Angiomyolipoma with Long-Term Follow up: A Case Report with Unique Clinicopathologic and Genomic Profile
    Liwei Jia, Vandana Panwar, Michelle Parmley, Elena Lucas, Ivan Pedrosa, Payal Kapur
    International Journal of Surgical Pathology.2022; 30(1): 86.     CrossRef
  • Perivascular epithelioid cell tumor of the lung: A case report and literature review
    Shaofu Yu, Shasha Zhai, Qian Gong, Xiaoping Hu, Wenjuan Yang, Liyu Liu, Yi Kong, Lin Wu, Xingxiang Pu
    Thoracic Cancer.2022; 13(17): 2542.     CrossRef
  • Cytopathology of extra-renal perivascular epithelioid cell tumor (PEComa): a series of 7 cases and review of the literature
    Sintawat Wangsiricharoen, Tatianna C. Larman, Paul E. Wakely, Momin T. Siddiqui, Syed Z. Ali
    Journal of the American Society of Cytopathology.2021; 10(2): 175.     CrossRef
  • Clear cell sugar tumour: a rare tumour of the lung
    Sarah Page, Matthew S. Yong, Alka Sinha, Pankaj Saxena
    ANZ Journal of Surgery.2020;[Epub]     CrossRef
  • Perivascular Epithelioid Cell Tumors (PEComas) of the Orbit
    Panagiotis Paliogiannis, Giuseppe Palmieri, Francesco Tanda, Antonio Cossu
    Journal of Pathology and Translational Medicine.2017; 51(1): 7.     CrossRef
Brief Case Reports
A Rare Case of Pulmonary Arteriovenous Hemangioma Presenting as a Peribronchial Mass
Soomin Ahn, Sejin Jung, Jong Ho Cho, Tae Sung Kim, Joungho Han
J Pathol Transl Med. 2016;50(3):243-245.   Published online November 17, 2015
DOI: https://doi.org/10.4132/jptm.2015.10.15
  • 7,082 View
  • 56 Download
  • 2 Citations
PDF

Citations

Citations to this article as recorded by  
  • Incidental discovery of a large complicated arteriovenous haemangioma
    Alberto Anthony Goizueta, Peter Libbey, Anthony Moulton, Rabih El-Bizri
    BMJ Case Reports.2017; : bcr-2016-218759.     CrossRef
  • Pulmonary Arteriovenous Fistula: Clinical and Histologic Spectrum of Four Cases
    Soomin Ahn, Joungho Han, Hong Kwan Kim, Tae Sung Kim
    Journal of Pathology and Translational Medicine.2016; 50(5): 390.     CrossRef
Soft Tissue Roasi-Dorfman Disease with Features of IgG4-Related Disease in a Patient with a History of Acute Myeloid Leukemia
Cheol Keun Park, Eun Kyung Kim, Ji-Ye Kim, Hayoung Woo, Mi Jang, Hyang Sook Jeong, Woo Ick Yang, Sang Kyum Kim
J Pathol Transl Med. 2016;50(3):246-249.   Published online November 17, 2015
DOI: https://doi.org/10.4132/jptm.2015.10.08
  • 6,564 View
  • 54 Download
PDF

JPTM : Journal of Pathology and Translational Medicine